Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brii BiosciencesFRA:7SS -1.07%33 Earnings Yield (Joel Greenblatt) % is 20.62% as of Dec. 2025, which is 62% above its 10-year median of 12.72. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,325 Biotechnology companies, Brii Biosciences ranks worse than 75471.62% on this metric.
Brii Biosciences's Enterprise Value for the quarter that ended in Dec. 2025 was €-138.74 Mil.
Brii Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-26.63 Mil. Brii Biosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 20.62%.
The historical rank and industry rank for Brii Biosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:7SS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -206.38 Med: 12.72 Max: 17435.46
Current: 14.92
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Brii Biosciences was 17435.46%. The lowest was -206.38%. And the median was 12.72%.
FRA:7SS's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -9.86
vs FRA:7SS: 14.92
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Brii Biosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Brii Biosciences Earnings Yield (Joel Greenblatt) % Related Terms
Brii Biosciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Brii Biosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Brii Biosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 20.62% mean?
Brii Biosciences (FRA:7SS) has a Earnings Yield (Joel Greenblatt) % of 20.62% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Brii Biosciences and its competitors. This is 62% above median its historical median of 12.72. According to the industry distribution chart, Brii Biosciences ranks #999999 out of 1325 companies in the Biotechnology industry.
Is Brii Biosciences' Earnings Yield (Joel Greenblatt) % too high?
Brii Biosciences' current Earnings Yield (Joel Greenblatt) % of 20.62% is 62% above median its 10-year median of 12.72. Based on the distribution chart, Brii Biosciences ranks #999999 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #999999 out of 1325 companies for Earnings Yield (Joel Greenblatt) %. This places Brii Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current Earnings Yield (Joel Greenblatt) % is 20.62%, which is 62% above median its own 10-year median of 12.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current Earnings Yield (Joel Greenblatt) % of 20.62%. The current Earnings Yield (Joel Greenblatt) % is 20.62%, which is 62% above median its 10-year median of 12.72. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current Earnings Yield (Joel Greenblatt) % is 20.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
